Damora Therapeutics, Inc.
DMRA
$20.96
$0.050.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 266.16% | 139.43% | -36.66% | -29.51% | -41.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,085.49% | 911.67% | -17.81% | -25.78% | -54.73% |
| Operating Income | -1,085.49% | -911.67% | 17.81% | 25.78% | 54.73% |
| Income Before Tax | -996.05% | -2,873.66% | 19.17% | 35.18% | 53.79% |
| Income Tax Expenses | 2,000.00% | 650.00% | -- | -90.48% | -- |
| Earnings from Continuing Operations | -996.84% | -2,877.84% | 19.31% | 35.61% | 53.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -996.84% | -2,877.84% | 19.31% | 35.61% | 53.75% |
| EBIT | -1,085.49% | -911.67% | 17.81% | 25.78% | 54.73% |
| EBITDA | -1,087.59% | -913.32% | 17.81% | 25.83% | 54.78% |
| EPS Basic | 57.72% | -2,543.31% | 30.38% | 47.19% | 62.06% |
| Normalized Basic EPS | 57.76% | -925.34% | 30.26% | 34.95% | 62.09% |
| EPS Diluted | 57.72% | -2,543.31% | 30.38% | 47.19% | 62.06% |
| Normalized Diluted EPS | 57.76% | -925.34% | 30.26% | 34.95% | 62.09% |
| Average Basic Shares Outstanding | 2,494.49% | 12.66% | 15.90% | 21.94% | 21.90% |
| Average Diluted Shares Outstanding | 2,494.49% | 12.66% | 15.90% | 21.94% | 21.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |